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ABSTRACT 1 
 2 
Background: The pro-myelinating effects of leukemia inhibitory factor (LIF) 3 
and other cytokines of the gp130 family, including oncostatin M (OSM) and 4 
ciliary neurotrophic factor (CNTF), have long been known, but controversial 5 
results have also been reported. We recently overexpressed erythropoietin 6 
receptor (EPOR) in rat central glia-4 (CG4) oligodendrocyte progenitor cells 7 
(OPCs) to study the mechanisms mediating the pro-myelinating effects of 8 
erythropoietin (EPO). In this study, we investigated the effect of co-treatment 9 
with EPO and LIF.  10 
Methods: Gene expression in undifferentiated and differentiating CG4 cells in 11 
response to EPO and LIF was analysed by DNA microarrays and by RT-12 
qPCR. Experiments were performed in biological replicates of N ≥ 4. 13 
Functional annotation and biological term enrichment was performed using 14 
DAVID (Database for Annotation, Visualization and Integrated Discovery). 15 
The gene-gene interaction network was visualised using STRING (Search 16 
Tool for the Retrieval of Interacting Genes). 17 
Results: In CG4 cells treated with 10 ng/ml of EPO and 10 ng/ml of LIF, 18 
EPO-induced myelin oligodendrocyte glycoprotein (MOG) expression, 19 
measured at day 3 of differentiation, was inhibited ≥ 4-fold (N=5, P < 0.001). 20 
Inhibition of EPO-induced MOG was also observed with OSM and CNTF. 21 
Analysis of the gene expression profile of CG4 differentiating cells treated for 22 
20 h with EPO and LIF revealed LIF inhibition of EPO-induced genes involved 23 
in lipid transport and metabolism, previously identified as positive regulators of 24 
myelination in this system. In addition, among the genes induced by LIF, and 25 
not by differentiation or by EPO, the role of suppressor of cytokine signaling 3 26 
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(SOCS3) and toll like receptor 2 (TLR2) as negative regulators of myelination 1 
was further explored. LIF-induced SOCS3 was associated with MOG 2 
inhibition; Pam3, an agonist of TLR2, inhibited EPO-induced MOG 3 
expression, suggesting that TLR2 is functional and its activation decreases 4 
myelination.  5 
Conclusions: Cytokines of the gp130 family may have negative effects on 6 
myelination, depending on the cytokine environment.  7 
 8 
BACKGROUND  9 
Oligodendrocytes (OLs), the myelinating cells of the central nervous system 10 
(CNS), produce the myelin sheath that provides physical protection and 11 
metabolic support to the axons and allows efficient conduction of action 12 
potential [1]. In chronic inflammatory diseases, such as multiple sclerosis 13 
(MS), damage to OLs causes demyelination, impairs axonal function and 14 
leads to progressive degeneration of axons [2, 3]. 15 
Remyelination, the process by which OL progenitor cells (OPCs) differentiate 16 
and mature to produce myelin that wrap demyelinated axons, can occur in the 17 
adult brain, where a wide-spread population of OPCs is present. 18 
Remyelination is usually highly efficient after injury and in the first stages of 19 
MS, but declines with aging and disease progression. Remyelination failure is 20 
a major determinant of progressive axonal degeneration and permanent 21 
neurological disability in chronic demyelinating diseases. Since OPCs are 22 
present in adult aging brain and in MS lesions, a block in differentiation and 23 
not a lack of OPCs seems responsible for remyelination failure [2, 4, 5]. 24 
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The main immunomodulating drugs approved for MS can delay disease 1 
progression but do not prevent progressive disability since do not repair 2 
existing damage. Remyelinating therapies are needed. In the last years, 3 
several remyelinating strategies have been attempted, and drugs that inhibit 4 
negative signals (e.g. antibodies to LINGO-1) or provide positive stimulation 5 
(e.g. clemastine fumarate) are in the translational pipeline, but no 6 
remyelinating drugs are currently available [4, 6-8]. 7 
The observations that remyelination can be achieved in aging brain when 8 
appropriate exogenous factors are provided [9] and transplantation of 9 
neuronal precursors increases remyelination mainly by immunomodulatory 10 
mechanisms [10] suggest that direct administration of neuroprotective factors, 11 
as opposed to transplantation of stem cells, might be a good remyelinating 12 
strategy. 13 
In the last twenty years, erythropoietin (EPO) has emerged as a potential 14 
candidate for neuroprotective and neuroregenerative treatment in injury and 15 
disease of the nervous system [11]. Interestingly, EPO improves cognitive 16 
performance in healthy animals and humans and in disease, including in MS 17 
[12-14]. Although the mechanism is still largely unknown, we and others 18 
showed that EPO acts directly on OLs to increase myelination in vitro and in 19 
vivo [15-18]. In a recent study aimed at identifying cytokines exhibiting 20 
protective and regenerative functions similar to EPO by “functional clustering”, 21 
leukemia inhibitory factor (LIF) emerged as one of the cytokines functionally 22 
similar to EPO [19]. 23 
LIF is a member of the interleukin-6 (IL-6) cytokine family that signals through 24 
the LIF receptor (LIFR) and the cytokine receptor glycoprotein 130 (gp130), 25 
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the latter shared with all the other cytokines of the IL-6 family, including ciliary 1 
neurotrophic factor (CNTF) and oncostatin M (OSM). LIF downstream 2 
signaling pathways include the JAK/STAT3, the PI3K/AKT and the 3 
MAPK/ERK pathways [20, 21]. 4 
LIF is a pleiotropic cytokine that can have diverse and opposite effects on 5 
different cell types, resulting in stimulation or inhibition of cell proliferation, 6 
differentiation and inflammation [20-25]. It is currently believed to play a 7 
crucial role in the response to injury, particularly in the CNS [22]. Its 8 
expression is increased in cerebral ischemia, spinal cord injury, Alzheimer’s 9 
disease, Parkinson’s disease, seizure and MS [20, 22, 26, 27].  10 
In the CNS, LIF can act on immune, neuronal and glial cells [21]. Many 11 
studies point to a direct action on OLs. In particular, LIF is required in 12 
development for the correct maturation of OLs;  in addition, in vivo and in 13 
vitro, both endogenous and exogenous LIF protect OLs from cell death and 14 
increase their proliferation, differentiation and maturation [20-22, 28-30].  15 
Studies in LIF knock-out mice and exogenous LIF administration have 16 
highlighted its protective action in many models of demyelination [20-22, 30, 17 
31], suggesting the possible therapeutic use of LIF and LIF inducers in 18 
demyelinating diseases, including MS [22, 32, 33].  19 
Coadministration of neuroprotective agents rather than a single agent may be 20 
more effective. In this regard, EPO was previously reported to synergise with 21 
insulin-like growth factor (IGF)-1 to protect against neuronal damage [34, 35].  22 
We have previously used an in vitro model of myelination, CG4 OPC 23 
transduced to overexpress erythropoietin receptor (EPOR), to study the 24 
mechanisms by which EPO increases myelin gene expression [18]. Aim of 25 
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this study was to investigate whether co-treatment with EPO and LIF was 1 
more effective than EPO alone and the mechanisms involved. Surprisingly, 2 
we found that LIF strongly inhibited EPO-induced myelination. By gene 3 
expression profiling, we investigated the mechanisms mediating LIF inhibitory 4 
effects at the early stage of the OL differentiation process. 5 
 6 
METHODS 7 
Cell culture and generation of CG4 cells expressing EPOR  8 
Rat CG4 OPC overexpressing the EPO receptor (CG4-EPOR) were 9 
generated and cultured as reported in our previous studies [16, 18]. As 10 
previously shown, wild type CG4 do not express EPOR and do not respond to 11 
EPO [16]. However, primary OLs express low levels of EPOR under 12 
physiological conditions [15], and EPOR is induced in the CNS in pathologies 13 
where EPO has protective functions [36]; in particular, injury induces EPOR 14 
expression in OLs [37]. By overexpressing EPOR in CG4 cells, we set up an 15 
in vitro system that allowed us to characterise the mechanisms mediating 16 
EPO differentiating and myelinating effects in OLs, mimicking an in vivo 17 
situation of injury or disease, where EPOR would be up-regulated. 18 
CG4-EPOR cells, for simplicity referred to as CG4, were used throughout this 19 
study. Briefly, CG4 cells were cultured in poly-L-ornithine-coated 6-well plates 20 
(320,000 cells in 4 ml of medium per well). They were maintained at the 21 
progenitor stage by culture in growth medium (GM), consisting of Dulbecco’s 22 
modified Eagle medium (DMEM) (Sigma-Aldrich) supplemented with biotin 23 
(10 ng/ml), basic fibroblast growth factor (bFGF; 5 ng/ml), platelet-derived 24 
growth factor (PDGF; 1 ng/ml), N1 supplement (all from Sigma-Aldrich) and 25 
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30% B104-conditioned medium, obtained as previously reported [16, 18]. 1 
After overnight culture, the cells were induced to differentiate  into OLs by 2 
switching to differentiation-promoting medium (DM), consisting of DMEM-F12 3 
(Invitrogen/ThermoFisher Scientific) supplemented with progesterone (3 4 
ng/ml), putrescine (5 µg/ml), sodium selenite (4 ng/ml), insulin (12.5 µg/ml), 5 
transferrin (50 µg/ml), biotin (10 ng/ml), thyroxine (0.4 µg/ml) and glucose (3 6 
g/l) (all from Sigma-Aldrich), as reported [16, 18]. Undifferentiated cells are 7 
bipolar; after 2 days of differentiation the cells acquire about 90% of multipolar 8 
morphology. Differentiated CG4 cells express myelin proteins, including MOG, 9 
a marker of myelin deposition in these cells [38, 39]. After 3 h in DM, some of 10 
the cells were treated with recombinant human EPO (Creative Dynamics), 11 
recombinant mouse LIF (Sigma-Aldrich), recombinant rat OSM (Peprotech), 12 
recombinant rat CNTF (Peprotech), or Pam3CSK4 (Pam3; InvivoGen). 13 
Human EPO is approximately 80% homologous to rodent EPO, and it is 14 
biologically active on rat cells [18]. Mouse and rat LIF share 92% sequence 15 
homology [40], and mouse LIF is biologically active on rat cells [41].  16 
RNA extraction 17 
For the microarray experiment, total RNA was extracted and analysed as 18 
reported, using the miRNeasy system and protocol (QIAGEN) [18]. For all the 19 
other experiments, total RNA was extracted with QIAzol (QIAGEN), following 20 
the instructions of the manufacturer, and RNA purity and concentration were 21 
determined using a NanoDrop ND-1000 (NanoDrop 22 
Technologies/ThermoFisher Scientific). 23 
RT-qPCR 24 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
                                                                                                                   Gyetvai et al. 8 
Reverse transcription (RT) and real time qPCR were carried out as reported  1 
[18, 42], using TaqMan® gene expression assays (Applied 2 
Biosystems/ThermoFisher Scientific) and Brilliant III qPCR master mix 3 
(Stratagene/Agilent Technologies). Gene expression was quantified using the 4 
ΔΔCt method, according to Applied Biosystems’ guidelines. Results were 5 
normalized to HPRT1 expression (reference gene) and expressed as fold 6 
change (FC) or as log2 FC vs one of the control samples, chosen as the 7 
calibrator, as previously reported [42].  8 
Microarrays 9 
All experimental conditions were performed in quadruplicate; undifferentiated 10 
cells were cultured in quadruplicate but only 3 random samples were used for 11 
microarray analysis and all of the 4 samples for qPCR validation. Results from 12 
27 arrays are analysed and presented in this study: 3 undifferentiated (undif) 13 
and 4 differentiated (dif), 4 differentiated+EPO (EPO), 4 14 
differentiated+EPO+LIF (EPO+LIF) at each time point (at 4 h and 23 h of 15 
differentiation; 1 h and 20 h after treatment with EPO and LIF respectively). 16 
RNA was amplified, labelled and hybridised onto Single Colour SurePrint G3 17 
Rat GE 8x60K Microarrays (AMADID:028279; Agilent) at Oxford Gene 18 
Technology, Oxford, UK. Following hybridisation, the arrays were scanned to 19 
derive the array images. Feature extraction software v10.7.3.1 was used to 20 
generate the array data from the images.  21 
Microarray Data Analysis  22 
Raw data in standard format from the microarray experiment have been 23 
deposited in the Gene Expression Omnibus (GEO) database of the National 24 
Center for Biotechnology Information (NCBI) [43] and are accessible through 25 
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GEO Series accession number GSE84687 (http://www.ncbi.nlm.nih.gov/geo). 1 
Raw data were normalised and analysed using GeneSpring (Agilent) and 2 
Excel (Microsoft) software. Transcript expression levels (log2 of the 3 
gProcessed Signal) between the experimental groups were compared by 4 
Student’s t test, obtaining uncorrected P values. Subsequent multiple 5 
comparison corrections were performed using the Benjamini-Hochberg (BH) 6 
False Discovery Rate (FDR) procedure, obtaining adjusted P values (BH adj. 7 
P values).  Fold change in the expression was calculated as the ratio between 8 
the average of the gProcessed Signals of the various groups and expressed 9 
as log2. Differences in expression with a BH adj. P value < 0.05 and an 10 
absolute fold change ≥ 1.5 (log2 fold change ≥ 0.58) were considered 11 
statistically significant.  12 
Functional annotation and biological term enrichment was performed using 13 
the DAVID v6.8 database (Database for Annotation, Visualization and 14 
Integrated Discovery) available online (https://david-d.ncifcrf.gov) [44]. 15 
Categories with P values < 0.05 were considered significantly enriched.  16 
Gene-gene interaction networks were visualised using the STRING v10.5 17 
database (Search Tool for the Retrieval of Interacting Genes/Proteins) 18 
available online (http://string-db.org). STRING assigns to each reported 19 
functional association a confidence score, which is dependent on both the 20 
experimental method on which the functional association prediction is based, 21 
and on the reliability of computational approaches used for prediction. We 22 
used all active prediction methods, and a confidence score > 0.4. 23 
 24 
RESULTS 25 
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LIF induces MOG with a bell-shaped dose response curve 1 
CG4 cells, a largely used in vitro model of myelination, can be differentiated to 2 
produce myelin proteins, including myelin basic protein (MBP), a marker of 3 
differentiation, and MOG, a marker of myelin deposition 4 
[38, 39]. In previous studies, we have validated this model and shown that 5 
expression of MOG mRNA correlated with production of the protein, 6 
measured by western blot [16]. Therefore, in this study we measured MOG 7 
mRNA as  a marker of  myelination in differentiated CG4 cells. 8 
CG4 cells were differentiated for 3 days in DM with or without increasing 9 
concentrations of LIF ranging from 0.004 to 10 ng/ml. LIF increased MOG 10 
expression with a peak at 0.2 ng/ml and had no effect at the higher dose of 10 11 
ng/ml, showing a bell-shaped dose response curve (Fig. 1a). In contrast, our 12 
previous results had shown that in these cells EPO still increased MOG 13 
expression at high doses, up to 400 ng/ml, although the expression plateaus 14 
after 10 ng/ml [16]. 15 
 16 
LIF inhibits EPO-induced MOG expression 17 
To investigate whether LIF synergised with EPO in increasing MOG 18 
expression, the cells were co-stimulated with EPO at 10 ng/ml and with LIF at 19 
0.2 and 10 ng/ml. No synergistic or additive effect was observed; surprisingly, 20 
LIF markedly inhibited EPO-induced MOG expression at the high dose (10 21 
ng/ml, Fig. 1b), and some inhibition was also observed at the low dose (0.2 22 
ng/ml, Fig. 1c), which had a positive effect on MOG induction when added 23 
alone (Fig.1a). Since EPO at high doses still increased MOG expression in 24 
these cells, as mentioned above and reported in a previous study [16], 25 
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whereas LIF was less effective at high dose (10 ng/ml) than at low dose (0.2 1 
ng/ml; Fig. 1a),  these results suggest the LIF might induce a negative 2 
feedback that inhibits both its own and EPO’s pro-myelinating effects.  3 
Of note, LIF at 10 ng/ml inhibited also EPO-induced myelin basic protein 4 
(MBP) expression at the same time point (at day 3 of differentiation): MBP 5 
mRNA as FC vs control, mean ± SD, N=8; EPO: 3.7 ± 1.3, P < 0.001 vs 6 
control; EPO+LIF: 1.5 ± 0.4, P < 0.001 vs EPO alone by two-tailed Student’s 7 
t-test). 8 
 9 
LIF-induced changes in gene expression 10 
To investigate the mechanisms by which LIF inhibits EPO-induced myelin 11 
gene expression, we performed a gene expression microarray study to 12 
identify the genes regulated by LIF in cells co-cultured with EPO and LIF, in 13 
which EPO-induced myelin gene expression was inhibited. We reasoned that 14 
co-culture with LIF might inhibit the effect of EPO by two mechanisms: i) 15 
inhibiting the expression of “positive regulators” of myelination increased by 16 
EPO; ii) increasing the expression of “negative regulators” of myelination, 17 
which are likely to be unchanged or decreased by differentiation or by EPO. 18 
Analysis of the transcripts regulated by differentiation and further regulated by 19 
addition of EPO at 1 h and 20 h has been reported elsewhere [18]. Here we 20 
focussed on the genes regulated by LIF, selected by comparing EPO+LIF vs 21 
EPO at 1 h and 20 h and setting a fold change (FC) cut-off of 1.5 (log2 FC 22 
0.58) and P value < 0.05 after applying the BH correction for multiple tests. 23 
 24 
Negative regulators of myelination induced by LIF at 1 h  25 
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The gene expression profile of EPO-treated CG4 cells at 1 h and the effect of 1 
differentiation alone, previously reported [18], is summarised in Fig. 2a; 2 
differentiation affected 878 genes, of which 461 were upregulated and 417 3 
downregulated; treatment of differentiating cells with EPO for 1 h affected only 4 
5 genes, which were all upregulated. Only 3 of these were affected and 5 
further increased by LIF (Fig. 2a and Additional File 1).  6 
Since at the early time point LIF did not inhibit any EPO-induced gene, we 7 
focussed on the idea that it might induce negative regulators of myelination, 8 
whose expression would likely be either unchanged or decreased by culture in 9 
DM with or without EPO. When comparing EPO+LIF vs EPO, 82 genes were 10 
increased (Fig. 2a). Of these, 7 genes were excluded because they were also 11 
increased by differentiation alone (4, Additional File 2) or by EPO (3, 12 
Additional File 3). Therefore 75 genes that were either downregulated or not 13 
changed by differentiation, not altered by EPO and finally upregulated by LIF 14 
remained.  15 
Network analysis of the remaining 75 genes (28+47, Fig. 2a) using the 16 
STRING database highlighted hubs centered on STAT3 and SOCS3 which 17 
included Myd88, part of toll-like receptor (TLR) signaling (Fig. 2b). A list of all 18 
the 75 genes, their fold change in expression levels by LIF (EPO+LIF vs EPO) 19 
and by differentiation (differentiated vs undifferentiated) is reported in 20 
Additional File 3.  21 
 22 
EPO-induced positive regulators of myelination inhibited by LIF at 20 h 23 
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The gene expression profile of EPO-treated CG4 cells and the effect of 1 
differentiation at 20 h have been previously reported [18]. In Fig. 3a, the 2 
genes affected by LIF have been included. 3 
At this time point EPO increased the expression of a number of genes, 4 
potential positive regulators of myelination, including 43 genes upregulated 5 
also by differentiation alone and 113 unaffected by differentiation.  Addition of 6 
LIF decreased 7 of the 43 genes increased by EPO and differentiation, and 9 7 
of the 113 genes increased only by EPO, as summarized in the Venn diagram 8 
in Fig. 3b (left). We focussed on the 16 putative positive regulators of 9 
myelination inhibited by LIF (green arrows, Fig. 3b), listed in Table 1. 10 
Functional annotation analysis of this subset of genes using the DAVID 11 
software highlighted enriched gene ontology biological process (GO:BP) and 12 
KEGG pathways categories involved in fatty acid transport, storage and 13 
oxidation; genes belonging to these categories included CD36, Pnlip, Plin2, 14 
Ppargc1a (Table 2). Of note, LIF inhibited also Ptpre, a protein tyrosine 15 
phosphatase which, among other effects, inhibits MAPK/ERK activation and 16 
that we previously identified as one of the top EPO-induced genes [18].  17 
Negative regulators of myelination induced by LIF at 20 h  18 
As at the 1 h time point, we then searched for potential LIF-induced negative 19 
regulators at 20 h.  These were selected by comparing EPO+LIF and EPO 20 
and setting a cut-off of FC > 1.5 (log2 FC > 0.58) and BH adj. P value < 0.05. 21 
As shown in Fig. 3a and in the Venn diagram in Fig. 3b (right), among the 22 
transcripts unchanged by either EPO and/or differentiation alone, we identified 23 
256 genes increased by addition of LIF; out of 1,272 genes decreased by 24 
differentiation, 69 genes were increased by LIF; among the 37 genes 25 
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downregulated by EPO, 2 were increased by LIF. In total, 327 genes 1 
unchanged or decreased by differentiation or EPO were increased by LIF (full 2 
list Additional File 4). 3 
STRING interaction analysis of the 71 genes induced by LIF and also 4 
decreased by differentiation (69) or EPO (2) (right red arrows, Fig. 3b), and 5 
therefore more likely to be putative negative regulators of myelination, 6 
highlighted a network of highly connected genes focused around STAT3, 7 
SOCS3 and TLR2 (Fig. 3c). 8 
 9 
High expression of LIF-induced SOCS3 is associated with reduced MOG 10 
expression 11 
Since SOCS3, downstream of STAT3, was highly induced by LIF at both time 12 
points, and its expression in OLs can inhibit LIF-induced myelination in vivo in 13 
mice [30], we explored further its involvement in LIF-mediated inhibition of 14 
myelination.  15 
The mRNA expression of SOCS3 from the microarray experiment was 16 
validated by RT-qPCR using the same RNA used for the microarray 17 
experiment; inhibition of SOCS3 by differentiation and induction by LIF at 1 h, 18 
reported in Additional File 3, were confirmed (SOCS3 mRNA as log2 FC, 19 
mean ± SD, N=4;  dif vs undif: -2.8 ± 0.2, P < 0.001; EPO+LIF vs EPO: 1.9 ± 20 
0.3,  P < 0.001 by two-tailed Student’s t-test).  21 
In independent experiments, SOCS3 expression was dose-dependently 22 
induced by LIF (Fig. 4a). Furthermore, co-stimulation of EPO-treated cells 23 
with LIF which, as shown in Fig. 1b, inhibits EPO-induced MOG expression, 24 
induced high levels of SOCS3 at 1 h (Fig. 4b). 25 
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The association between MOG inhibition and induction of high levels of 1 
SOCS3 was confirmed with OSM or CNTF, cytokines also belonging to the IL-2 
6 family.  At concentrations equimolar to the high dose of LIF (10 ng/ml), also 3 
OSM and CNTF inhibited EPO-induced MOG (Fig. 4c), and induced high 4 
levels of SOCS3 at 1 h (SOCS3 mRNA as FC vs control, mean ± SD, N=4; 5 
OSM: 8.1 ± 1.7, P < 0.001; CNTF: 5.2 ± 1.7, P < 0.01 by two-tailed Student’s 6 
t-test). Of note, at a lower dose (0.13 ng/ml), equimolar to 0.2 ng/ml of LIF, 7 
OSM induced MOG expression, whereas CNTF had no effect (SOCS3 mRNA 8 
as FC vs control, mean ± SD, N=4; OSM: 3.2 ± 0.7, P < 0.001; CNTF: 1.4 ± 9 
0.2, P = 0.19 by two-tailed Student’s t-test). 10 
 11 
TLR2 engagement inhibits EPO-induced MOG 12 
Among the negative regulators induced by LIF, TLR2 was also highlighted as 13 
a highly connected hub by STRING analysis at 20 h (Fig. 3c). Microarray 14 
expression of TLR2 was validated by RT-qPCR using the same RNA used for 15 
the microarray experiment, confirming the inhibition of TLR2 by differentiation 16 
and the very high induction by LIF at 20 h reported in Additional File 4 (TLR2 17 
mRNA as log2 FC, mean ± SD, N=4;  dif vs undif: -1.5 ± 0.5, P < 0.01; 18 
EPO+LIF vs EPO: 3.6 ± 0.3,  P < 0.001 by two-tailed Student’s t-test).  19 
We therefore assessed the functional relevance of this finding using the TLR2 20 
agonist Pam3. As shown in Fig. 4d, TLR2 activation inhibited EPO-induced 21 
MOG expression at the same extent as LIF and potentiated LIF inhibition. 22 
 23 
DISCUSSION 24 
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Although there is ample evidence in the literature that LIF and other cytokines 1 
of the IL-6 family, including CNTF, have pro-myelinating activities in vivo and 2 
in vitro [20-22, 33], we report here that LIF can inhibit myelination in vitro. 3 
Specifically, in CG4 OPC induced to differentiate into OLs in the presence of 4 
EPO, co-treatment with LIF inhibited EPO-induced MOG expression. Of note, 5 
LIF inhibition was observed in CG4 cells transduced to overexpress EPOR, 6 
and therefore optimised to respond to EPO. We had previously used this in 7 
vitro system to study the mechanisms by which EPO increased myelin gene 8 
expression [18], using MOG as a readout since its expression is associated 9 
with myelin deposition in these cells [39]. Compared to cells incubated in DM 10 
alone, treatment with EPO consistently induced high levels of MOG 11 
expression, which were strongly inhibited by LIF. The effect was more marked 12 
at high LIF concentrations (10 ng/ml), but inhibition was also noted at lower 13 
concentrations (0.2 ng/ml), which per se could slightly increase MOG 14 
expression. All together these observations highlight the strength of the 15 
inhibitory effect of LIF. 16 
Our data may seem in contrast with many studies observing LIF pro-17 
myelinating effects [20-22, 33]. However, no effect of LIF on OL differentiation 18 
had been previously described [45-47]; interestingly, one study reported 19 
inhibitory effects  of high LIF doses (more than 5 ng/ml) on OPC differentiation 20 
[29]. The ability of LIF to inhibit the pro-myelinating effects of other cytokines 21 
had not previously been reported.  22 
LIF activates STAT3, which has a key role in myelination  [48]. However, LIF 23 
signaling is tightly regulated. LIF-induced SOCS3, downstream of STAT3, 24 
inhibits STAT3 phosphorylation and excessive induction of inflammatory 25 
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genes [49], and is one of the main mechanisms through which LIF inhibits IL-1 
6-induced differentiation of T helper (Th)17 cells [23]. In the present study, 2 
LIF-induced SOCS3 expression was associated with a reduction of EPO-3 
induced MOG at high concentration of LIF.  In addition, also OSM and CNTF, 4 
cytokines of the  IL-6 family, used at equimolar LIF concentrations at which 5 
they induced similar levels of SOCS3 as compared to LIF (reported above in 6 
the Results section), inhibited EPO-induced MOG expression. These 7 
observations, together with previous results documenting increased 8 
myelination in SOCS3 knock-out mice [30], suggest that SOCS3 might play a 9 
role in LIF inhibition of MOG expression. SOCS3 induction might explain the 10 
lower levels of MOG observed at high doses of LIF compared to low dose, 11 
and inhibition of EPO-induced MOG. Of note, SOCS3 can inhibit EPO-12 
induced STAT5 activation [50, 51]. 13 
We investigated whether LIF might directly inhibit the expression of positive 14 
regulators of myelination induced by EPO. By gene expression profiling, we 15 
found that LIF downregulated genes involved in lipid transport and 16 
metabolism previously found to be increased by EPO, including CD36, 17 
Ppargc1a, Pnlip and Plin2 [18]. Preferential downregulation of these genes by 18 
LIF strengthens the hypothesis that they might have a role in mediating EPO 19 
myelinating effects. 20 
LIF inhibitory effects reported here cannot exclusively be correlated with an 21 
action on differentiated cells; LIF might also act on undifferentiated cells.   22 
In this regard, LIF inhibited PTPRE, a tyrosine phosphatase induced by EPO 23 
that, among other effects, inhibits MAPK/ERK phosphorylation. We had 24 
previously shown that inhibitors of ERK in this system potentiate myelination, 25 
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in support of the hypothesis that activation of ERK might sustain proliferation 1 
of OPCs and inhibit the start of differentiation [18]. Both EPO and LIF can 2 
induce ERK activation [18, 20]. However, EPO induces the feedback inhibitor 3 
PTPRE. Inhibition of PTPRE by LIF might prolong ERK activation in OPCs, 4 
inhibiting differentiation.  5 
In addition, other than being pro-myelinating cytokines, LIF and other 6 
members of the IL-6 family, such as CNTF, are essential in development for 7 
inducing astrocyte differentiation. LIF can also increase astrocyte 8 
differentiation in vitro, although the presence of extracellular matrix factors 9 
may be required [20]. CG4 cells are bipotential OL type-2 astrocyte (O-2A) 10 
progenitors that can be induced to differentiate into type-2 astrocytes or into 11 
mature OLs [38, 39]. In primary OLs and CG4 cells LIF can induce the 12 
astrocyte marker GFAP [46, 52], an observation that we have confirmed 13 
(Additional File 4). It is therefore possible that LIF, if present at the very early 14 
stages of the OL differentiation process, could interfere by inducing astrocyte 15 
differentiation.  Although this is a very controversial issue, the presence of O-16 
2A progenitors in vivo, and even in pathological conditions, has been 17 
suggested [53, 54].  18 
Among the possible negative regulators induced by LIF, we noticed 19 
components of the TLR pathways, including TLR2 and Myd88, an adaptor 20 
protein used by almost all TLRs. Other than microbial products, the TLRs 21 
recognize endogenous danger-associated molecular patterns (DAMPs) 22 
released from injured tissues which regulate inflammatory responses [55]. All 23 
cells of the CNS express the TLRs, including OLs which preferentially express 24 
TLR2 and TLR3 [56, 57]. TLR2 is upregulated in experimental models of MS 25 
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and in MS demyelinating lesions, where it is also expressed by OLs [57-59]; 1 
TLR2 activation inhibits OL maturation, an effect not shared by all TLRs [57]. 2 
We show here that TLR2 is functional in OLs, and its activation inhibits myelin 3 
gene expression.  4 
Whether TLR2 has a role in mediating LIF inhibitory effects will of course 5 
depend on the presence of TLR2 ligands. TLR2, by forming homodimers and 6 
heterodimers with TLR1 or TLR6, can bind a broad range of ligands, including 7 
Gram-positive bacterial cell wall components, endogenous DAMPs such as 8 
heat shock proteins (HSPs) and high mobility group protein B1 (HMGB1), and 9 
fragments of extracellular matrix (ECM) molecules, such as hyaluronan [60, 10 
61]. Of note, TLR2 ligands, including hyaluronan, HMGB1 and peptidoglycan, 11 
a component of Gram-positive bacteria, have been detected in EAE and in 12 
MS lesions [62-64], suggesting that LIF-induction of TLR2 in OLs might 13 
actually lead to inhibition of remyelination. 14 
Although LIF has an important role in promoting myelination [22, 28, 33], its 15 
pleiotropic nature, and its ability to induce proliferation inhibiting differentiation 16 
or vice versa, may result in negative myelinating effects at certain stages of 17 
the myelination process, likely when undifferentiated OL progenitors should 18 
stop proliferating and start differentiating. In pathological conditions, including 19 
MS, remyelination, especially at later disease stages, is insufficient to re-20 
establish motor and cognitive performance. MS lesions may contain large 21 
numbers of poorly differentiated OPCs and immature OLs, suggesting that in 22 
many cases the main cause of remyelination failure is not a lack of OPCs, but 23 
rather an inability of these cells to differentiate into mature myelin producing 24 
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cells [2, 4, 5]. The presence of LIF in MS lesions [26] might contribute to 1 
inhibit OPC differentiation and remyelination. 2 
Moreover, our findings show that, when considering the action of cytokines on 3 
myelination, one should consider that they act on a tightly regulated network, 4 
where each cytokine can affect the action of another. Identifying these 5 
regulatory networks may be important as different cytokines may be up- or 6 
down-regulated in disease conditions and this may have pharmacological 7 
relevance when cytokines are administered as neuroprotective or 8 
neuroreparative agents. Although the effectiveness of EPO in MS is unclear 9 
and recent clinical trials have not shown an efficacy [65], research is still 10 
active on EPO mimetics or derivatives with different biological properties [66, 11 
67]; clinical trials with EPO in optic neuritis are ongoing after positive 12 
indications from phase 2 trials  [68, 69] and its use to improve traumatic brain 13 
injury is still open [70]. Likewise, there is interest in the potential use of LIF in 14 
the therapy of MS [22, 33]. The tight regulation of LIF signaling pathways that 15 
might negatively affect remyelination, shown here, needs to be taken into 16 
account in designing combination therapies and dose-finding studies. 17 
Additionally, increased blood and cerebrospinal fluid levels of LIF [27], IL-11 18 
[71], CNTF [72] and IL-6 [73] have been found in MS patients, thus raising the 19 
possibility of them affecting the response to EPO. 20 
Of course we should bear in mind the limitations of our study. The use of a 21 
cell line, although largely used for basic studies on myelination, limits the 22 
external validity of our findings, and only in vivo experiments in models of 23 
demyelination could indicate the in vivo relevance of the pathways that we 24 
have identified. 25 
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 1 
CONCLUSION 2 
This study reports that the IL-6 family cytokine LIF can inhibit EPO-induced 3 
myelin gene expression in OLs. LIF’s promyelinating effects have long been 4 
known, but controversial results have also been reported. The pleiotropic 5 
activities of LIF, which can inhibit or stimulate proliferation or differentiation 6 
and exhibit inflammatory or anti-inflammatory action, together with the tight 7 
inhibitory feedback mechanisms that regulate its signaling pathways, and its 8 
ability to induce negative regulators, such as TLR2, can translate into 9 
inhibition of myelination, depending on the stage of OL differentiation and on 10 
the cytokine environment. Further studies on the mechanisms by which 11 
endogenous cytokines positively and negatively affect myelination may lead to 12 
the identification of therapeutic targets and new drugs essential to improve 13 
remyelination in demyelinating diseases. 14 
 15 
ADDITIONAL FILES 16 
Additional File 1. Genes increased by EPO in differentiating cells at 1 h. 17 
Genes changed more than 1.5-fold (absolute log2 FC > 0.58), BH adj. P value 18 
< 0.05 in EPO-treated vs untreated differentiating cells are listed; ns=not 19 
significant. There were no genes decreased by EPO at this time point. The 20 
relative change in differentiating (dif) vs undifferentiated (undif) cells and in 21 
EPO+LIF vs EPO-treated cells are also reported. *Represented by 2 probes 22 
consistently increased by EPO of which only the most significantly changed 23 
one is shown (xlsx file). 24 
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Additional File 2. Genes increased by LIF and by differentiation at 1 h. 1 
These genes have been identified by comparing EPO+LIF vs EPO and 2 
differentiating (dif) vs undifferentiated (undif) cells, setting a threshold of log2 3 
FC ≥ 0.58 and BH adj. P value < 0.05. *Represented by 2 probes consistently 4 
increased by LIF of which only the most significantly changed one is shown 5 
(xlsx file). 6 
Additional File 3. Genes increased by LIF and unchanged or decreased 7 
by differentiation or EPO at 1 h. The genes increased more than 1.5-fold 8 
(log2 FC ≥ 0.58), BH adj. P value < 0.05 in EPO+LIF vs EPO-treated 9 
differentiating cells are listed; ns=not significant. For genes represented by 2 10 
probes (*) consistently increased by LIF, only the one increased more 11 
significantly is shown (xlsx file). 12 
Additional File 4. Genes increased by LIF and unchanged or decreased 13 
by differentiation or EPO at 20 h. The genes increased more than 1.5-fold 14 
(log2 FC ≥ 0.58), BH adj. P value < 0.05 in EPO+LIF vs EPO-treated 15 
differentiating cells are listed; ns=not significant. For genes represented by 2 16 
probes (*) consistently increased by LIF, only the one increased more 17 
significantly is shown (xlsx file).  18 
 19 
ABBREVIATIONS 20 
BH: Benjamini-Hochberg; CD36: cluster of differentiation 36; CG4: central 21 
glia-4; CNS: central nervous system; CNTF: ciliary neurotrophic factor; 22 
DAMP: damage-associated molecular patterns; DAVID: Database for 23 
Annotation, Visualization and Integrated Discovery; DM: differentiation 24 
medium; EPO: erythropoietin; EPOR: erythropoietin receptor; ERK: 25 
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extracellular signal-regulated kinases; GM: growth medium; GO:BP: gene 1 
ontology biological process; gp130: glycoprotein 130; HPRT1: hypoxanthine 2 
phosphoribosyltransferase 1; HSP: heat shock protein; JAK: janus kinase; 3 
LIF: leukemia inhibitory factor; LIFR: leukemia inhibitory factor receptor; 4 
MAPK: mitogen-activated protein kinase; MOG: myelin oligodendrocyte 5 
glycoprotein; MS: multiple sclerosis; Myd88: myeloid differentiation primary 6 
response 88; O-2A: oligodendrocyte-type-2 astrocyte; OL: oligodendrocyte; 7 
OPC: oligodendrocyte progenitor cell; OSM: oncostatin M; PI3K: 8 
phosphatidylinositol-3-kinase; Plin2: perilipin 2; Pnlip: pancreatic lipase; 9 
Ppargc1a: peroxisome proliferator-activated receptor gamma coactivator 1 10 
alpha; Ptpre: protein tyrosine phosphatase receptor type E; qPCR: 11 
quantitative polymerase chain reaction; RT: reverse transcription; SOCS3: 12 
suppressor of cytokine signaling 3; STAT3: signal transducer and activator of 13 
transcription 3; STRING: Search Tool for the Retrieval of Interacting Genes; 14 
TLR: toll like receptor. 15 
 16 
ACKNOWLEDGMENTS 17 
The authors thank Alexander Annenkov for providing the CG4-EPOR cells 18 
used in this study. 19 
 20 
FUNDING 21 
Supported by the RM Philips Trust (PG), the Brighton Centre for Regenerative 22 
Medicine and Devices (CRMD), University of Brighton (GG) and the Brighton 23 
and Sussex Medical School as part of the Independent Research Project of 24 
CR. 25 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
                                                                                                                   Gyetvai et al. 24 
 1 
AVAILABILITY OF DATA AND MATERIALS 2 
The microarray datasets generated during the current study are available in 3 
the GEO database of NCBI (http://www.ncbi.nlm.nih.gov/geo) at GEO Series 4 
accession number GSE84687. 5 
 6 
AUTHORS’ CONTRIBUTIONS 7 
GG, CR, LH, MM performed experiments, analyzed and interpreted results; 8 
GG, MM, PG designed experiments; GG, MM and PG wrote the manuscript; 9 
all authors critically revised and approved the final manuscript. 10 
 11 
ETHICS APPROVAL 12 
Not applicable. 13 
 14 
CONSENT FOR PUBLICATION 15 
Not applicable. 16 
 17 
COMPETING INTERESTS 18 
The authors declare they have no competing interests as defined 19 
by Molecular Medicine, or other interests that might be perceived to influence 20 
the results and discussion reported in this paper. 21 
 22 
REFERENCES 23 
1. Philips T, Rothstein JD: Oligodendroglia: metabolic supporters of 24 
neurons. J Clin Invest 2017, 127(9):3271-3280. 25 
2. Franklin RJ, Gallo V: The translational biology of remyelination: 26 
past, present, and future. Glia 2014, 62(11):1905-1915. 27 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
                                                                                                                   Gyetvai et al. 25 
3. Tauheed AM, Ayo JO, Kawu MU: Regulation of oligodendrocyte 1 
differentiation: Insights and approaches for the management of 2 
neurodegenerative disease. Pathophysiology 2016, 23(3):203-210. 3 
4. Kremer D, Kury P, Dutta R: Promoting remyelination in multiple 4 
sclerosis: current drugs and future prospects. Mult Scler 2015, 5 
21(5):541-549. 6 
5. Chamberlain KA, Nanescu SE, Psachoulia K, Huang JK: 7 
Oligodendrocyte regeneration: Its significance in myelin 8 
replacement and neuroprotection in multiple sclerosis. 9 
Neuropharmacology 2016, 110(Pt B):633-643, doi: 10 
10.1016/j.neuropharm.2015.10.010. 11 
6. Cadavid D, Balcer L, Galetta S, Aktas O, Ziemssen T, Vanopdenbosch 12 
L, Frederiksen J, Skeen M, Jaffe GJ, Butzkueven H et al: Safety and 13 
efficacy of opicinumab in acute optic neuritis (RENEW): a 14 
randomised, placebo-controlled, phase 2 trial. Lancet Neurol 2017, 15 
16(3):189-199. 16 
7. Green AJ, Gelfand JM, Cree BA, Bevan C, Boscardin WJ, Mei F, 17 
Inman J, Arnow S, Devereux M, Abounasr A et al: Clemastine 18 
fumarate as a remyelinating therapy for multiple sclerosis 19 
(ReBUILD): a randomised, controlled, double-blind, crossover 20 
trial. Lancet  2017, 390(10111):2481-2489. 21 
8. Bove RM, Green AJ: Remyelinating Pharmacotherapies in Multiple 22 
Sclerosis. Neurotherapeutics 2017, 14(4):894-904. 23 
9. Ruckh JM, Zhao JW, Shadrach JL, van Wijngaarden P, Rao TN, 24 
Wagers AJ, Franklin RJ: Rejuvenation of regeneration in the aging 25 
central nervous system. Cell Stem Cell 2012, 10(1):96-103. 26 
10. Martino G, Pluchino S: The therapeutic potential of neural stem 27 
cells. Nat Rev Neurosci 2006, 7(5):395-406. 28 
11. Sargin D, Friedrichs H, El-Kordi A, Ehrenreich H: Erythropoietin as 29 
neuroprotective and neuroregenerative treatment strategy: 30 
comprehensive overview of 12 years of preclinical and clinical 31 
research. Best Pract Res Clin Anaesthesiol 2010, 24(4):573-594. 32 
12. Ehrenreich H, Fischer B, Norra C, Schellenberger F, Stender N, Stiefel 33 
M, Siren AL, Paulus W, Nave KA, Gold R et al: Exploring 34 
recombinant human erythropoietin in chronic progressive 35 
multiple sclerosis. Brain 2007, 130(Pt 10):2577-2588. 36 
13. Robinson S, Winer JL, Chan LAS, Oppong AY, Yellowhair TR, Maxwell 37 
JR, Andrews N, Yang Y, Sillerud LO, Meehan WP, 3rd et al: Extended 38 
Erythropoietin Treatment Prevents Chronic Executive Functional 39 
and Microstructural Deficits Following Early Severe Traumatic 40 
Brain Injury in Rats. Front Neurol 2018, 9:451. 41 
14. Li XB, Zheng W, Ning YP, Cai DB, Yang XH, Ungvari GS, Ng CH, 42 
Wang CY, Xiang YT: Erythropoietin for Cognitive Deficits 43 
Associated with Schizophrenia, Bipolar Disorder, and Major 44 
Depression: A Systematic Review. Pharmacopsychiatry 2018, 45 
51(3):100-104. 46 
15. Sugawa M, Sakurai Y, Ishikawa-Ieda Y, Suzuki H, Asou H: Effects of 47 
erythropoietin on glial cell development; oligodendrocyte 48 
maturation and astrocyte proliferation. Neurosci Res 2002, 49 
44(4):391-403. 50 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
                                                                                                                   Gyetvai et al. 26 
16. Cervellini I, Annenkov A, Brenton T, Chernajovsky Y, Ghezzi P, 1 
Mengozzi M: Erythropoietin (EPO) increases myelin gene 2 
expression in CG4 oligodendrocyte cells through the classical 3 
EPO receptor. Mol Med 2013, 19:223-229. 4 
17. Hassouna I, Ott C, Wustefeld L, Offen N, Neher RA, Mitkovski M, 5 
Winkler D, Sperling S, Fries L, Goebbels S et al: Revisiting adult 6 
neurogenesis and the role of erythropoietin for neuronal and 7 
oligodendroglial differentiation in the hippocampus. Mol Psychiatry 8 
2016, 21(12):1752-1767. 9 
18. Gyetvai G, Hughes T, Wedmore F, Roe C, Heikal L, Ghezzi P, 10 
Mengozzi M: Erythropoietin Increases Myelination in 11 
Oligodendrocytes: Gene Expression Profiling Reveals Early 12 
Induction of Genes Involved in Lipid Transport and Metabolism. 13 
Front Immunol 2017, 8:1394. 14 
19. Mengozzi M, Ermilov P, Annenkov A, Ghezzi P, Pearl F: Definition of 15 
a Family of Tissue-Protective Cytokines Using Functional Cluster 16 
Analysis: A Proof-of-Concept Study. Front Immunol 2014, 5:115. 17 
20. Nicola NA, Babon JJ: Leukemia inhibitory factor (LIF). Cytokine 18 
Growth Factor Rev 2015, 26(5):533-544. 19 
21. Davis SM, Pennypacker KR: The role of the leukemia inhibitory 20 
factor receptor in neuroprotective signaling. Pharmacol Ther 2018, 21 
183:50-57. 22 
22. Slaets H, Hendriks JJ, Stinissen P, Kilpatrick TJ, Hellings N: 23 
Therapeutic potential of LIF in multiple sclerosis. Trends Mol Med 24 
2010, 16(11):493-500. 25 
23. Cao W, Yang Y, Wang Z, Liu A, Fang L, Wu F, Hong J, Shi Y, Leung 26 
S, Dong C et al: Leukemia inhibitory factor inhibits T helper 17 cell 27 
differentiation and confers treatment effects of neural progenitor 28 
cell therapy in autoimmune disease. Immunity 2011, 35(2):273-284. 29 
24. Linker RA, Kruse N, Israel S, Wei T, Seubert S, Hombach A, Holtmann 30 
B, Luhder F, Ransohoff RM, Sendtner M et al: Leukemia inhibitory 31 
factor deficiency modulates the immune response and limits 32 
autoimmune demyelination: a new role for neurotrophic cytokines 33 
in neuroinflammation. J Immunol 2008, 180(4):2204-2213. 34 
25. Ulich TR, Fann MJ, Patterson PH, Williams JH, Samal B, Del Castillo J, 35 
Yin S, Guo K, Remick DG: Intratracheal injection of LPS and 36 
cytokines. V. LPS induces expression of LIF and LIF inhibits acute 37 
inflammation. Am J Physiol 1994, 267(4 Pt 1):L442-446. 38 
26. Vanderlocht J, Hellings N, Hendriks JJ, Vandenabeele F, Moreels M, 39 
Buntinx M, Hoekstra D, Antel JP, Stinissen P: Leukemia inhibitory 40 
factor is produced by myelin-reactive T cells from multiple 41 
sclerosis patients and protects against tumor necrosis factor-42 
alpha-induced oligodendrocyte apoptosis. J Neurosci Res 2006, 43 
83(5):763-774. 44 
27. Mashayekhi F, Salehi Z: Expression of leukemia inhibitory factor in 45 
the cerebrospinal fluid of patients with multiple sclerosis. J Clin 46 
Neurosci 2011, 18(7):951-954. 47 
28. Stankoff B, Aigrot MS, Noel F, Wattilliaux A, Zalc B, Lubetzki C: Ciliary 48 
neurotrophic factor (CNTF) enhances myelin formation: a novel 49 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
                                                                                                                   Gyetvai et al. 27 
role for CNTF and CNTF-related molecules. J Neurosci 2002, 1 
22(21):9221-9227. 2 
29. Ishibashi T, Dakin KA, Stevens B, Lee PR, Kozlov SV, Stewart CL, 3 
Fields RD: Astrocytes promote myelination in response to 4 
electrical impulses. Neuron 2006, 49(6):823-832. 5 
30. Emery B, Cate HS, Marriott M, Merson T, Binder MD, Snell C, Soo PY, 6 
Murray S, Croker B, Zhang JG et al: Suppressor of cytokine 7 
signaling 3 limits protection of leukemia inhibitory factor receptor 8 
signaling against central demyelination. Proc Natl Acad Sci U S A 9 
2006, 103(20):7859-7864. 10 
31. Marriott MP, Emery B, Cate HS, Binder MD, Kemper D, Wu Q, Kolbe 11 
S, Gordon IR, Wang H, Egan G et al: Leukemia inhibitory factor 12 
signaling modulates both central nervous system demyelination 13 
and myelin repair. Glia 2008, 56(6):686-698. 14 
32. Vela L, Caballero I, Fang L, Liu Q, Ramon F, Diez E, de Los Frailes M: 15 
Discovery of Enhancers of the Secretion of Leukemia Inhibitory 16 
Factor for the Treatment of Multiple Sclerosis. J Biomol Screen 17 
2016, 21(5):437-445. 18 
33. Metcalfe SM: LIF and multiple sclerosis: One protein with two 19 
healing properties. Mult Scler Relat Disord 2018, 20:223-227. 20 
34. Digicaylioglu M, Garden G, Timberlake S, Fletcher L, Lipton SA: Acute 21 
neuroprotective synergy of erythropoietin and insulin-like growth 22 
factor I. Proc Natl Acad Sci U S A 2004, 101(26):9855-9860. 23 
35. Kang YJ, Digicaylioglu M, Russo R, Kaul M, Achim CL, Fletcher L, 24 
Masliah E, Lipton SA: Erythropoietin plus insulin-like growth factor-25 
I protects against neuronal damage in a murine model of human 26 
immunodeficiency virus-associated neurocognitive disorders. Ann 27 
Neurol 2010, 68(3):342-352. 28 
36. Siren AL, Knerlich F, Poser W, Gleiter CH, Bruck W, Ehrenreich H: 29 
Erythropoietin and erythropoietin receptor in human 30 
ischemic/hypoxic brain. Acta Neuropathol 2001, 101(3):271-276. 31 
37. Ott C, Martens H, Hassouna I, Oliveira B, Erck C, Zafeiriou MP, Peteri 32 
UK, Hesse D, Gerhart S, Altas B et al: Widespread expression of 33 
erythropoietin receptor in brain and its induction by injury. Mol 34 
Med 2015, 21(1):803-815, doi: 10.2119/molmed.2015.00192 35 
38. Louis JC, Magal E, Muir D, Manthorpe M, Varon S: CG-4, a new 36 
bipotential glial cell line from rat brain, is capable of 37 
differentiating in vitro into either mature oligodendrocytes or type-38 
2 astrocytes. J Neurosci Res 1992, 31(1):193-204. 39 
39. Solly SK, Thomas JL, Monge M, Demerens C, Lubetzki C, Gardinier 40 
MV, Matthieu JM, Zalc B: Myelin/oligodendrocyte glycoprotein 41 
(MOG) expression is associated with myelin deposition. Glia 1996, 42 
18(1):39-48. 43 
40. Willson TA, Metcalf D, Gough NM: Cross-species comparison of the 44 
sequence of the leukaemia inhibitory factor gene and its protein. 45 
Eur J Biochem 1992, 204(1):21-30. 46 
41. Takahashi A, Takahashi Y, Matsumoto K, Miyata K: Synergistic 47 
effects of insulin-like growth factor II (IGF-II) with leukemia 48 
inhibiting factor (LIF) on establishment of rat pluripotential cell 49 
lines. J Vet Med Sci 1995, 57(3):553-556. 50 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
                                                                                                                   Gyetvai et al. 28 
42. Mengozzi M, Cervellini I, Villa P, Erbayraktar Z, Gokmen N, Yilmaz O, 1 
Erbayraktar S, Manohasandra M, Van Hummelen P, Vandenabeele P 2 
et al: Erythropoietin-induced changes in brain gene expression 3 
reveal induction of synaptic plasticity genes in experimental 4 
stroke. Proc Natl Acad Sci U S A 2012, 109(24):9617-9622. 5 
43. Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky 6 
M, Marshall KA, Phillippy KH, Sherman PM, Holko M et al: NCBI GEO: 7 
archive for functional genomics data sets--update. Nucleic Acids 8 
Res 2013, 41(Database issue):D991-995. 9 
44. Huang da W, Sherman BT, Lempicki RA: Systematic and integrative 10 
analysis of large gene lists using DAVID bioinformatics resources. 11 
Nat Protoc 2009, 4(1):44-57. 12 
45. Barres BA, Schmid R, Sendnter M, Raff MC: Multiple extracellular 13 
signals are required for long-term oligodendrocyte survival. 14 
Development 1993, 118(1):283-295. 15 
46. Kahn MA, De Vellis J: Regulation of an oligodendrocyte progenitor 16 
cell line by the interleukin-6 family of cytokines. Glia 1994, 17 
12(2):87-98. 18 
47. Park SK, Solomon D, Vartanian T: Growth factor control of CNS 19 
myelination. Dev Neurosci 2001, 23(4-5):327-337. 20 
48. Steelman AJ, Zhou Y, Koito H, Kim S, Payne HR, Lu QR, Li J: 21 
Activation of oligodendroglial Stat3 is required for efficient 22 
remyelination. Neurobiol Dis 2016, 91:336-346. 23 
49. Yasukawa H, Ohishi M, Mori H, Murakami M, Chinen T, Aki D, Hanada 24 
T, Takeda K, Akira S, Hoshijima M et al: IL-6 induces an anti-25 
inflammatory response in the absence of SOCS3 in macrophages. 26 
Nat Immunol 2003, 4(6):551-556. 27 
50. Sasaki A, Yasukawa H, Shouda T, Kitamura T, Dikic I, Yoshimura A: 28 
CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by 29 
binding the EPO receptor and JAK2. J Biol Chem 2000, 30 
275(38):29338-29347. 31 
51. Bachmann J, Raue A, Schilling M, Bohm ME, Kreutz C, Kaschek D, 32 
Busch H, Gretz N, Lehmann WD, Timmer J et al: Division of labor by 33 
dual feedback regulators controls JAK2/STAT5 signaling over 34 
broad ligand range. Mol Syst Biol 2011, 7:516. 35 
52. Gresle MM, Butzkueven H, Perreau VM, Jonas A, Xiao J, Thiem S, 36 
Holmes FE, Doherty W, Soo PY, Binder MD et al: Galanin is an 37 
autocrine myelin and oligodendrocyte trophic signal induced by 38 
leukemia inhibitory factor. Glia 2015, 63(6):1005-1020. 39 
53. Franklin RJ, Blakemore WF: Glial-cell transplantation and plasticity 40 
in the O-2A lineage--implications for CNS repair. Trends Neurosci 41 
1995, 18(3):151-156. 42 
54. Virard I, Coquillat D, Bancila M, Kaing S, Durbec P: Oligodendrocyte 43 
precursor cells generate pituicytes in vivo during 44 
neurohypophysis development. Glia 2006, 53(3):294-303. 45 
55. Lee H, Lee S, Cho IH, Lee SJ: Toll-like receptors: sensor molecules 46 
for detecting damage to the nervous system. Curr Protein Pept Sci 47 
2013, 14(1):33-42. 48 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
                                                                                                                   Gyetvai et al. 29 
56. Bsibsi M, Ravid R, Gveric D, van Noort JM: Broad expression of Toll-1 
like receptors in the human central nervous system. J Neuropathol 2 
Exp Neurol 2002, 61(11):1013-1021. 3 
57. Sloane JA, Batt C, Ma Y, Harris ZM, Trapp B, Vartanian T: 4 
Hyaluronan blocks oligodendrocyte progenitor maturation and 5 
remyelination through TLR2. Proc Natl Acad Sci U S A 2010, 6 
107(25):11555-11560. 7 
58. Zekki H, Feinstein DL, Rivest S: The clinical course of experimental 8 
autoimmune encephalomyelitis is associated with a profound and 9 
sustained transcriptional activation of the genes encoding toll-like 10 
receptor 2 and CD14 in the mouse CNS. Brain Pathol 2002, 11 
12(3):308-319. 12 
59. Esser S, Gopfrich L, Bihler K, Kress E, Nyamoya S, Tauber SC, 13 
Clarner T, Stope MB, Pufe T, Kipp M et al: Toll-Like Receptor 2-14 
Mediated Glial Cell Activation in a Mouse Model of Cuprizone-15 
Induced Demyelination. Mol Neurobiol 2018, 55(8):6237-6249, doi: 16 
10.1007/s12035-017-0838-2. 17 
60. Piccinini AM, Midwood KS: DAMPening inflammation by modulating 18 
TLR signalling. Mediators Inflamm 2010; 2010:672395, doi: 19 
10.1155/2010/672395 20 
61. Miranda-Hernandez S, Baxter AG: Role of toll-like receptors in 21 
multiple sclerosis. Am J Clin Exp Immunol 2013, 2(1):75-93. 22 
62. Back SA, Tuohy TM, Chen H, Wallingford N, Craig A, Struve J, Luo NL, 23 
Banine F, Liu Y, Chang A et al: Hyaluronan accumulates in 24 
demyelinated lesions and inhibits oligodendrocyte progenitor 25 
maturation. Nat Med 2005, 11(9):966-972. 26 
63. Visser L, Melief MJ, van Riel D, van Meurs M, Sick EA, Inamura S, 27 
Bajramovic JJ, Amor S, Hintzen RQ, Boven LA et al: Phagocytes 28 
containing a disease-promoting Toll-like receptor/Nod ligand are 29 
present in the brain during demyelinating disease in primates. Am 30 
J Pathol 2006, 169(5):1671-1685. 31 
64. Andersson A, Covacu R, Sunnemark D, Danilov AI, Dal Bianco A, 32 
Khademi M, Wallstrom E, Lobell A, Brundin L, Lassmann H et al: 33 
Pivotal advance: HMGB1 expression in active lesions of human 34 
and experimental multiple sclerosis. J Leukoc Biol 2008, 35 
84(5):1248-1255. 36 
65. Schreiber K, Magyari M, Sellebjerg F, Iversen P, Garde E, Madsen CG, 37 
Bornsen L, Romme Christensen J, Ratzer R, Siebner HR et al: High-38 
dose erythropoietin in patients with progressive multiple 39 
sclerosis: A randomized, placebo-controlled, phase 2 trial. Multiple 40 
sclerosis (Houndmills, Basingstoke, England) 2017, 23(5):675-685. 41 
66. Culver DA, Dahan A, Bajorunas D, Jeziorska M, van Velzen M, Aarts L, 42 
Tavee J, Tannemaat MR, Dunne AN, Kirk RI et al: Cibinetide 43 
Improves Corneal Nerve Fiber Abundance in Patients With 44 
Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic 45 
Pain. Invest Ophthalmol Vis Sci 2017, 58(6):BIO52-BIO60. 46 
67. Bonnas C, Wustefeld L, Winkler D, Kronstein-Wiedemann R, Dere E, 47 
Specht K, Boxberg M, Tonn T, Ehrenreich H, Stadler H et al: EV-3, an 48 
endogenous human erythropoietin isoform with distinct 49 
functional relevance. Sci Rep 2017, 7(1):3684. 50 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
                                                                                                                   Gyetvai et al. 30 
68. Suhs KW, Hein K, Sattler MB, Gorlitz A, Ciupka C, Scholz K, 1 
Kasmann-Kellner B, Papanagiotou P, Schaffler N, Restemeyer C et al: 2 
A randomized, double-blind, phase 2 study of erythropoietin in 3 
optic neuritis. Ann Neurol 2012, 72(2):199-210. 4 
69. Diem R, Molnar F, Beisse F, Gross N, Druschler K, Heinrich SP, 5 
Joachimsen L, Rauer S, Pielen A, Suhs KW et al: Treatment of optic 6 
neuritis with erythropoietin (TONE): a randomised, double-blind, 7 
placebo-controlled trial-study protocol. BMJ Open 2016, 8 
6(3):e010956. 9 
70. Counter CM, Botelho FM, Wang P, Harley CB, Bacchetti S: 10 
Stabilization of short telomeres and telomerase activity 11 
accompany immortalization of Epstein-Barr virus-transformed 12 
human B lymphocytes. J Virol 1994, 68(5):3410-3414. 13 
71. Zhang X, Tao Y, Chopra M, Dujmovic-Basuroski I, Jin J, Tang Y, 14 
Drulovic J, Markovic-Plese S: IL-11 Induces Th17 Cell Responses in 15 
Patients with Early Relapsing-Remitting Multiple Sclerosis. J 16 
Immunol 2015, 194(11):5139-5149. 17 
72. Massaro AR, Soranzo C, Carnevale A: Cerebrospinal-fluid ciliary 18 
neurotrophic factor in neurological patients. Eur Neurol 1997, 19 
37(4):243-246. 20 
73. Wullschleger A, Kapina V, Molnarfi N, Courvoisier DS, Seebach JD, 21 
Santiago-Raber ML, Hochstrasser DF, Lalive PH: Cerebrospinal fluid 22 
interleukin-6 in central nervous system inflammatory diseases. 23 
PloS One 2013, 8(8):e72399. 24 
 25 
 26 
 27 
  28 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
                                                                                                                   Gyetvai et al. 31 
Table 1. Genes increased by EPO and inhibited by LIF at 20 h. 1 
 2 
  EPO+LIF vs EPO 
EPO vs 
differentiation 
ProbeName Gene Log2FC 
BH 
adj.P 
Log2FC 
BH 
adj.P 
A44P792784 Htr2c -1.98 6.0E-04 5.14 5.1E-05 
A64P128810 RGD1565355 -1.79 7.2E-04 5.11 9.3E-05 
A64P113795 LOC100365047 -1.58 1.2E-02 2.06 3.9E-03 
A64P057188 Shroom2* -1.52 5.5E-03 1.73 1.6E-02 
A64P054808 CD36* -1.47 1.1E-03 6.98 1.5E-04 
A44P305482 Ppargc1a -1.43 3.9E-03 1.48 1.6E-02 
A44P335776 Chodl -1.42 6.3E-03 1.89 5.9E-03 
A44P158758 Calcr -1.40 1.3E-02 1.78 1.9E-02 
A64P15946 Pmp2* -1.16 1.4E-03 5.24 1.5E-05 
A64P025432 LOC498829 -1.04 6.0E-03 1.06 1.1E-02 
A44P194803 Baalc -1.03 3.1E-03 1.93 7.0E-04 
A64P137130 Ptpre -0.94 1.4E-02 4.01 3.5E-04 
A44P254984 Pnlip -0.89 4.8E-03 0.92 5.2E-03 
A42P839964 Plin2 -0.79 8.7E-03 1.33 2.8E-03 
A42P826938 LRRTM1 -0.63 3.9E-03 1.11 6.4E-04 
A42P646991 Mag -0.59 1.7E-02 1.34 7.9E-03 
All the genes increased by EPO and inhibited by LIF at 20 h are listed. In bold  3 
the genes also increased by differentiation. The full list of the genes increased 4 
by EPO and differentiation at 20 h was previously reported [18]. *Genes 5 
represented by 2 probes consistently changed by EPO in the same direction, 6 
of which only the most significantly changed one is shown. 7 
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Table 2. Enriched KEGG pathways and GO:BP categories among the 1 
genes increased by EPO and inhibited by LIF at 20 h. 2 
 3 
 4 
DAVID Functional Annotation Chart Analysis showing the overrepresented 5 
GO:BP categories and KEGG pathways among the genes increased by EPO 6 
and decreased by LIF at 20 h. The fold enrichment and the significance of 7 
enrichment (P value) are reported. 8 
 9 
 10 
 11 
  12 
Category Term Fold 
enrichment 
Gene symbols P value 
KEGG Fat digestion and 
absorption 
87.7 Pnlip, CD36, RGD1565355 3.4E-04 
KEGG Adipocytokine 
signaling pathway 
44.5 CD36, Ppargc1a, RGD1565355  1.3E-
03 
GO:BP Intestinal 
cholesterol 
absorption 
730.6 PnlipP, CD36 2.5E-03 
KEGG Insulin resistance 30.3 CD36, Ppargc1a, RGD1565355 2.9E-03 
GO:BP Response to drug 11.1 CD36, Plin2, Htr2c, 
PPARGC1A 
3.7E-03 
KEGG AMPK signaling 
pathway 
26.3 CD36, PPARGC1A, 
RGD1565355 
3.8E-03 
GO:BP Cell surface 
receptor signaling 
pathway 
22.8 Calcr, CD36, RGD1565355 6.1E-03 
GO:BP Long-chain fatty 
acid transport 
243.5 CD36, Plin2 7.5E-03 
GO:BP Fatty acid 
oxidation 
182.7 CD36, Ppargc1a 1.0E-02 
GO:BP Lipid storage 108.2 CD36, Plin2 1.7E-02 
GO:BP Response to lipid 97.4 Pnlip, CD36 1.9E-02 
GO:BP Receptor 
internalization 
69.6 Calcr, CD36  2.6E-
02 
KEGG Malaria 37.7 CD36, RGD1565355 4.5E-02 
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Figure Legends  1 
 2 
Figure 1. LIF induces MOG mRNA with a bell-shaped dose-response 3 
curve and inhibits EPO-induced MOG expression. Cells cultured for one 4 
day in growth medium (GM) were switched to differentiation medium (DM). 5 
After 3 h in DM the cells were treated with the indicated concentrations of LIF 6 
(panel a) or with or without EPO (10 ng/ml) and LIF (10 ng/ml, panel b; 0.2 7 
ng/ml, panel c). MOG gene expression was measured by RT-qPCR at day 3 8 
of differentiation. Results are expressed as fold change (FC) vs one of the 9 
control samples (no LIF in panel a and ctr in panels b and c). Data are the 10 
mean ± SD of seven samples from two independent experiments assayed in 11 
duplicate (panel a) or of quadruplicate samples assayed in duplicate and 12 
representative or five (panel b) or two (panel c) independent experiments;  * P 13 
< 0.05, **P < 0.01, ***P < 0.001 vs control; § P < 0.01 vs EPO alone by two-14 
tailed Student’s t-test. 15 
 16 
Figure 2. Genes regulated by LIF at 1 h. Cells cultured for one day in GM 17 
were switched to DM; after 3 h EPO with or without LIF was added and cells 18 
were incubated for further 1 h. (a) Flow chart. Genes regulated by 19 
differentiation were selected by comparing differentiating (4 h culture with DM) 20 
vs undifferentiated cells; genes regulated by EPO by comparing EPO-treated 21 
(1 h) vs untreated differentiating cells; genes regulated by LIF by comparing 22 
EPO+LIF-treated (1 h) vs EPO-treated cells. Cut-off for selection was FC of 23 
1.5 (log2 FC of 0.58) and BH adj. P value < 0.05. The number of upregulated 24 
or downregulated genes resulting from filtering is indicated. Negative 25 
regulators induced by LIF and unchanged by differentiation or EPO (47) or 26 
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decreased by differentiation (28) are highlighted in red. (b) Gene-gene 1 
interaction network of the putative negative regulators increased by LIF at 1 h. 2 
All the genes increased by LIF and either unchanged by differentiation or EPO 3 
(47 genes, Fig. 2a) or decreased by differentiation alone (28 genes, Fig. 2a) 4 
were analysed with the STRING software and the gene-gene interaction 5 
network was visualised. None of the genes increased by LIF were decreased 6 
by EPO at this time point. Different line colours represent types of evidence 7 
for association: green line, neighbourhood evidence; red line, fusion evidence; 8 
purple line, experimental evidence; light blue line, database evidence; black 9 
line, co-expression evidence; blue line, co-occurrence evidence; yellow line, 10 
text mining evidence. The full list of all the 75 genes and the relative 11 
expression changes induced by LIF and by differentiation are reported in 12 
Additional File 3. 13 
 14 
Figure 3. Genes regulated by LIF at 20 h. Cells cultured for one day in GM 15 
were switched to DM; after 3 h EPO with or without LIF was added for 20 h. 16 
(a) Flow chart. Genes regulated by differentiation, EPO and LIF were selected 17 
as in the legend to Figure 2.  Positive regulators induced by EPO and 18 
inhibited by LIF are highlighted in green (16, of which 7 induced also by 19 
differentiation).  Negative regulators induced by LIF and unchanged by 20 
differentiation or EPO (256) or decreased by differentiation (69) or by EPO (2) 21 
are highlighted in red. (b) Venn diagrams showing positive regulators inhibited 22 
by LIF (left; EPO-induced genes unchanged or induced by differentiation, 9 23 
and 7 respectively, green arrows) and negative regulators induced by LIF 24 
(right; 256 unchanged by differentiation or EPO; 69 and 2 decreased by 25 
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differentiation or EPO respectively, red arrows). The genes changed in 1 
opposite directions by EPO and differentiation are not included in b. These 2 
are: 8 genes increased by differentiation but decreased by EPO and 21 genes 3 
increased by EPO but decreased by differentiation (a). In addition, the left 4 
diagram (positive regulators) does not include the genes decreased by LIF but 5 
also decreased by differentiation or EPO (4+1+48+131+27=211; a). The right 6 
diagram (negative regulators) does not include the genes increased by LIF 7 
but also increased by EPO or differentiation (13+1+75+5+43=137; a). Dif, 8 
differentiated; undif, undifferentiated. (c) Gene-gene interaction network of the 9 
putative negative regulators increased by LIF at 20 h. All the genes increased 10 
by LIF and decreased by differentiation alone (69 genes, panel a) or by EPO 11 
alone (2 genes, panel a) were analysed with the STRING software as 12 
described in the legend to Figure 2. The full list of all the 71 genes is reported 13 
in Additional File 4. 14 
 15 
Figure 4. Role of SOCS3 and TLR2 in mediating LIF inhibition. (a-b) LIF 16 
induction of SOCS3 is associated with a reduction in MOG expression (shown 17 
in Figure 1). Cells cultured for one day in GM were switched to DM; after 3 h 18 
they were treated with the indicated concentrations of LIF (a), or with or 19 
without EPO (10 ng/ml) and LIF (10 ng/ml; panel b). After 1 h, SOCS3 mRNA 20 
was measured by RT-qPCR. Results, expressed as fold change (FC) vs one 21 
of the control (ctr) samples (no LIF in panel a) are the mean  ± SD of 22 
quadruplicate samples assayed in duplicate and are representative of two 23 
independent experiments; * P < 0.05, ***P < 0.001 vs control (no LIF); § P < 24 
0.001 vs EPO by two-tailed Student’s t-test. (c) OSM and CNTF inhibit EPO-25 
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induced MOG expression. Cells cultured as above were treated with or 1 
without EPO (10 ng/ml) and OSM or CNTF (both at 6.5 ng/ml, equimolar 2 
concentrations to LIF 10 ng/ml). MOG gene expression was measured by RT-3 
qPCR at day 3. Results, expressed as above, are the mean ± SD of eight 4 
samples from two independent experiments assayed in duplicate; *** P < 5 
0.001 vs EPO alone; § P < 0.001 vs untreated by two-tailed Student’s t-test. 6 
(d) TLR2 engagement inhibits EPO-induced MOG expression. Cells were 7 
differentiated  in the absence or in the presence of EPO (10 ng/ml), with or 8 
without LIF (10 ng/ml) or Pam3 (1 µg/ml), a TLR2/1 ligand. MOG expression 9 
was measured at day 3 by RT-qPCR. Results, expressed as above, are the 10 
mean ± SD of quadruplicate samples assayed in duplicate and are 11 
representative of two independent experiments; ***P < 0.001 vs EPO alone; § 12 
P < 0.01 vs EPO+LIF by two-tailed Student’s t-test. 13 
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